Drug Profile
Hyaluronic acid/triamcinolone acetonide - Carbylan Therapeutics
Alternative Names: Hydros-TALatest Information Update: 15 Feb 2022
Price :
$50
*
At a glance
- Originator Carbylan BioSurgery
- Developer KalVista Pharmaceuticals
- Class Adjuvants; Analgesics; Anti-inflammatories; Antiallergics; Antiasthmatics; Antipsoriatics; Antirheumatics; Corticosteroids; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Glycosaminoglycans; Pregnadienes; Small molecules; Urologics
- Mechanism of Action Glucocorticoid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 15 Feb 2022 Discontinued - Phase-II for Pain in West Indies (Intra-articular)
- 15 Feb 2022 Discontinued - Phase-III for Pain in Europe, Canada, Australia, Netherlands Antilles, New Zealand (Intra-articular)
- 22 Nov 2016 Carbylan Therapeutics has been acquired and merged into KalVista Pharmaceuticals